Lipopolysaccharide based oral nanocarriers for the improvement of bioavailability and anticancer efficacy of curcumin
•We prepared curcumin loaded lipopolysaccharide nanocarriers (C-LPNCs).•LPNCs showed diffusion-controlled release of curcumin.•LPNCs showed enhanced oral bioavailability of curcumin.•C-LPNCs demonstrated higher cytotoxicity than pure curcumin.•C-LPNCs showed markedly enhanced in vivo anticancer effi...
Gespeichert in:
Veröffentlicht in: | Carbohydrate polymers 2015-10, Vol.130, p.9-17 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •We prepared curcumin loaded lipopolysaccharide nanocarriers (C-LPNCs).•LPNCs showed diffusion-controlled release of curcumin.•LPNCs showed enhanced oral bioavailability of curcumin.•C-LPNCs demonstrated higher cytotoxicity than pure curcumin.•C-LPNCs showed markedly enhanced in vivo anticancer efficacy as well as survival rate.
Soluthin MD®, a unique phosphatidylcholine-maltodextrin based hydrophilic lipopolysaccharide, which exhibits superior biocompatibility and bioavailability enhancer properties for poorly water soluble drug(s). Curcumin (CUR) is a potential natural anticancer drug with low bioavailability due to poor aqueous solubility. The study aims at formulation and optimization of CUR loaded lipopolysaccharide nanocarriers (C-LPNCs) to enhance oral bioavailability and anticancer efficacy in colon-26 tumor-bearing mice in vitro and in vivo. The Optimized C-LPNCs demonstrated favorable mean particle size (108±3.4nm) and percent entrapment efficiency (65.29±1.0%). Pharmacokinetic parameters revealed ∼130-fold increase in oral bioavailability and cytotoxicity studies demonstrated ∼23-fold reduction in 50% cell growth inhibition when treated with optimized C-LPNCs as compared to pure CUR. In vivo anticancer study performed with optimized C-LPNCs showed significant increase in efficacy compared with pure CUR. Thus, lipopolysaccharide nanocarriers show potential delivery strategy to improve oral bioavailability and anticancer efficacy of CUR in the treatment of colorectal cancer. |
---|---|
ISSN: | 0144-8617 1879-1344 |
DOI: | 10.1016/j.carbpol.2015.04.062 |